I guess the sky is the limit with LLY.
Earnings received well even though negative on EPS and a EPS miss.
Price appeared to be forming an M pattern but has made another leg up.
Resistance overhead.
No recommendation.
BEWARE of the dog, but that cat can be shady too (o:
Earnings does not look as if analysts expect a whole awful lot but you never know!
M pattern that could take this lower. Peak 2 is higher than peak 1 so possibly looking at a Shark (to the .886 or the 1.113 or a Cypher (to the .786 and measured from entire structure and the Shark is measured from the 1st peak) This could also be a NEN-Star (takes it to the...
LLY has given us Bearish RSI Confirmation at the 3.618 Fibonacci Extension and now looks to push below the $580 level. This could quickly devolve into LLY making a much deeper Bearish Retrace that would bring it below trend. At that point, we could very well see LLY come all the way back down to fill the gap at $163.42
Eli Lilly / LLY stopped its short term decline yesterday a little over the 1day MA50.
The green 1day candle signals the start of the new bullish phase inside this double Channel Up.
The 1day RSI is on a similar pattern as August 3rd.
Assuming a declining rate of growth on each Higher High, buy and target 670 (+30% from the recent bottom).
Follow us, like the...
Eli Lilly sues online pharmacies to ban US imports of fake Mounjaro.
Eli Lilly on Thursday said it sued 11 online pharmacies to stop them from importing, selling and distributing products claiming to contain the active ingredient in its diabetes drug Mounjaro, which is expected to be approved for weight loss later this year.
The Indianapolis-based drugmaker said...
Eli Lilly & Co. is a pharmaceutical company with a long history dating back to its founding by Eli Lilly in May 1876. The company is headquartered in Indianapolis, Indiana, and is engaged in the discovery, development, manufacture, and sale of pharmaceutical products. Their product portfolio includes a range of therapies in various therapeutic areas, such as...
Eli Lilly and Company (LLY) has long been one of our best investments a real gem that even withstood and was practically unaffected by the 2022 inflation crisis. For long we have been using the Fibonacci Channel to display LLY's parabolic nature having broken above the 2.0 Fibonacci extension last May.
This time the price reversed much quicker than technically...
Hello friends.
Eli Lilly has been catapulted into an extraordinary bubble, spurred on by the narrative of their weight loss drug being taken up by America's obese population. The price just seems to go up and up forever, and many traders likely think that it will go to infinity. But all bubbles must pop at some point, and we think that it's the perfect time for...
Eli Lilly has completed 3 red weeks in a row. The parabolic rise it is seeing for years is seen accurately on this Fibonacci Channel.
Every such price peak, pulled back to under the MA100 (1d), which is now at 492.43, in order to gather buyers.
Trading Plan:
1. Sell on the current market price.
Targets:
1. 490 (between the MA100 (1d) and the Fibonacci 2.0...
Eli Lilly has seen enormous growth over the past few years and in particularly in 2023. This Channel Up on the log chart's 1W timeframe is the best depiction of the long term trend. The 1W outlook got extremely overbought technically three weeks ago (RSI = 68.989, MACD = 46.590, ADX = 60.019) and is now correcting. The rejection took place at the top of the...
Hello There!
Welcome to my new analysis about LLY on several timeframe perspectives. LLY printed an major bullish breakout literally over night bouncing out of the range. In the recent times the pharma industry transformed into a eager bullish environment since the gains seen because of the "pandemic" and LLY is a stock already present since 1978 in the 19th...
Earlier this year we gave a strong buy signal on Eli Lilly and Company (LLY) on March 01 (see chart below) where we called for the most optimal buy entry exactly at the bottom of the bullish pattern:
The price has now hit (last week) the top of the 4 year logarithmic Channel Up, highly overbought with the RSI on the 1W time-frame reaching 84.30, breaking...
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Positive:
Yields high return on invested capital
Has raised its dividend for 8 consecutive years
13 analysts have revised their earnings upwards for the upcoming period
Prominent player in the Pharmaceuticals industry
Cash flows can sufficiently cover interest payments
...
If we close the day as we are now, we will have confirmed a 3 Line Strike, a Bearish PPO Arrow, and a break below the 5 EMA on the Daily Timeframe just above the 3.618 Fibonacci Extension. From there I would expect LLY to first Fill the gap at $451.50 and beyond that I think it will revisit the 200-day SMA around $350 and maybe even the 800-day EMA at around $285.
1) Ridiculously overvalued.
2) Coiled stochastics monthly.
3) Overbought on all timeframes.
4) Heavy institutional ownership.
5) Log chart shows channel. Linear chart shows extreme price deviation.
It can always go higher, as human stupidity is boundless, so just saying.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War
